Kistik Fibrozis ile İlişkili Diyabet: Bir Olgu Sunumu

Kistik fibrozis ile ilişkili diyabet (KFİD), kistik fibrozisin (KF) yaygın bir komplikasyonudur. Kistik fibrozis ile ilişkili diyabetin temel nedeni hastalarda yıllar içerisinde pankreas hasarının artması ile beraber pankreas adacık hücrelerinin kaybı ve insülin eksikliğinin gelişmesidir. Tedavideki amaç çocuk ve adolesanlarda normal büyüme ve gelişmenin ve kan glukoz regülasyonunun sağlanmasıdır. Tedavinin temelini insülin tedavisi ve tıbbi beslenme tedavisi oluşturur. İnsülin tedavisi, KFİD hastalarında akciğer fonksiyonunu stabilize eder ve beslenme durumunu iyileştirir. Kistik fibrozis ile ilişkili diyabetli hastalara yüksek enerji, yüksek yağ ve yüksek tuz içeren bir beslenme planı önerilmektedir. Karbonhidrat sayımı, insülin tedavisi alan hastalarda öğün öncesi insülin dozunun belirlenmesinde yararlıdır. Bu yazıda kliniğimizde izlenen KFİD’li bir çocuk olgunun medikal ve tıbbi beslenme tedavisi literatür derlemesi eşliğinde sunulmuştur.

Cystic Fibrosis Related Diabetes: A Case Report

Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis (CF). The main reason for CFRD is the increase of pancreatic damage in patients over the years, as well as the loss of pancreatic islet cells and the development of insulin deficiency. The purpose of treatment is to ensure normal growth and development in children and adolescents and to regulate blood glucose. The basis of the treatment is insulin therapy and medical nutrition therapy. Insulin therapy stabilizes lung function and improves nutritional status in patients with CFRD. A diet with high energy, high fat and high salt is recommended for patients with CFRD. Carbohydrate counting is useful in determining the pre-meal insulin dose in patients receiving insulin therapy. In this article, medical and medical nutritional therapy of the patient with CFRD, followed in our clinic, is presented with a review of the literature.

Kaynakça

1. Kayani K, Mohammed R, Mohiaddin, H. Cystic fibrosis-related diabetes. Frontiers in Endocrinology. 2018; 9:20:1-11.

2. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini C.L. ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatric Diabetes. 2018;19:64-74.

3. Türk Toraks Derneği. Kistik Fibrozis Tanı ve Tedavi Rehberi. Turk Thorac J. 2011;12(2):1-140.

4. O’Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Hormone research in Paediatrics. 2010;73(1):15-24.

5. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis–related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-31.

6. Litvin M, Nwachukwu S. Cystic fibrosis related diabetes: a unique challenge in diabetes care. Missouri Medicine. 2016;113(5):384-9.

7. Moran A, Brunzell C, Cohen R. C, Katz M, Marshall B. C, Onady G. CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis–related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708.

8. Koch D, Rainisio M, Madessani U. Presence of cystic fibrosis-related diabetes mellitus is tightly liked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001;32:343-50.

9. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr. 2001;90:515–9.

10. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane, F, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. The Journal of Pediatrics. 2008;152(4):540-5.

11. Kolouskova S, Zemkova D, Bartosova J. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 30 year prospective study. J Pediatr Endocrinol Metab. 2011;24:454-99.

12. Moran A, Pekow P, Grover P. Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009;32:1783-8.

13. Kaminski BA, Goldsweig B. K, Sidhaye A, Blackman S. M, Schindler T, Moran A. Cystic fibrosis related diabetes: Nutrition and growth considerations. Journal of Cystic Fibrosis. 2019;18:32-7.

14. Mohammed NH, Wolever TM. Effect of carbohydrate source on post-prandial blood glucose in subjects with type 1 diabetes treated with insulin lispro. Diabetes Research and Clinical Practice. 2004;65(1):29-35.

Kaynak Göster